Detection of Synchronous Primary Malignancies with ^{68}Ga-Labeled Prostate-Specific Membrane Antigen PET/CT in Patients with Prostate Cancer: Frequency in 764 Patients

Medhat M. Osman[1], Amir Iravani[2], Rodney J. Hicks[2,3], and Michael S. Hofman[2,3]

[1]Division of Nuclear Medicine, Department of Radiology, St. Louis University Hospital, St. Louis, Missouri; [2]Centre for Molecular Imaging, Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; and [3]Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia

We evaluated the incidence of synchronous primary malignancies in patients undergoing ^{68}Ga-labeled prostate-specific membrane antigen PET/CT for prostate cancer (PC). **Methods:** Reports for 764 PC patients were reviewed. Incidental lesions atypical for PC metastases and suggestive of a synchronous primary malignancy were identified. Follow-up was obtained to confirm etiology. **Results:** Lesions atypical for PC metastases were found in 49 (6.4%) of 764 patients, and a synchronous primary malignancy was confirmed in 5 patients (0.7%; 2 lung, 1 lymphoma, 1 thyroid, and 1 base of tongue). In 8 patients (1.0%), lesions were proven to be atypical metastases from PC. In 24 patients (3.1%), lesions had a benign etiology. Follow-up was not available in 12 patients (1.6%). **Conclusion:** Synchronous ^{68}Ga-labeled prostate-specific membrane antigen–avid malignancies were rare (0.7%) in PC patients; atypical lesions were more commonly unusual PC metastases (1.0%) or benign (3.1%).

Key Words: synchronous primary malignancy; prostate cancer; ^{68}Ga-PSMA; PET/CT

In the United States, prostate cancer (PC) is the most common cancer and the second most frequent cause of cancer-related death in men (1). Early diagnosis, accurate staging, and tumor characterization are critical for appropriate selection of patient-tailored therapy. CT, MRI, and bone scanning, although widely used in the diagnosis, staging, and restaging of PC, have suboptimal accuracy. This limitation was recently addressed by the introduction of ^{68}Ga-labeled prostate-specific membrane antigen (PSMA) PET/CT. Several studies revealed higher diagnostic accuracy of ^{68}Ga-PSMA PET/CT than of conventional imaging, including PET with other tracers (2–4). However, clinical experience with reading ^{68}Ga-PSMA PET/CT scans is limited, pending U.S. Food and Drug Administration approval and Centers for Medicare and Medicaid Services payment. Despite the promise of ^{68}Ga-PSMA, its uptake and avidity have been reported to be not completely specific to PC, with recent case reports of uptake in benign lesions as well as non-PC malignancies (5–13). The objective of the present study was to determine the incidence of synchronous ^{68}Ga-PSMA–avid malignancies in a large group of patients undergoing evaluation for known PC.

MATERIALS AND METHODS

Patient Population

A total of 764 patients (mean age, 68 y; range, 48–85) who had undergone ^{68}Ga-PSMA PET/CT from 2013 to 2016 for known PC (73 for staging and 691 for restaging) were included. This single-center retrospective study was approved by the Institutional Human Research Ethics Committee, with a waiver of informed consent of patients who had been scanned for clinical indications.

^{68}Ga-PSMA PET/CT Image Acquisition and Protocol

^{68}Ga was eluted from a ^{68}Ga/^{68}Ge generator (Isotope Technology Group) and compounded with hydroxybenzylethylenediamine diacetic acid (HBED)-PSMA11 (Advanced Biochemical Compounds). PET images were acquired approximately 60 min (range, 40–85) after injection of ^{68}Ga-HBED-PSMA11 at 2 MBq/kg (166 MBq; range, 91–246). Acquisition was performed on a GE Discovery PET/CT 690 or 710 scanner (GE Healthcare) or a Siemens Biograph 64 PET/CT scanner (Siemens Healthcare). CT was performed either with a low-dose noncontrast technique (old protocol) or 10 min (range, 8–15) after intravenous injection of 50 mL of iohexol (Omnipaque [GE Healthcare]; 300 g/mL) contrast medium for optimal ureteral enhancement (new protocol as of mid-2015).

Data Analysis

All reports from clinical ^{68}Ga-PSMA PET/CT were reviewed. We selected for further evaluation lesions with or without ^{68}Ga-PSMA uptake, lesions that were not previously detected by other modalities, and lesions that were considered atypical in location for PC metastases on PET/CT and that were interpreted by the reporting PET specialist as being suggestive of a synchronous primary malignancy. Histopathologic, imaging, and clinical follow-up was obtained to confirm the etiology of these findings.

RESULTS

Possible synchronous malignant tumors were reported in 49 (6.4%) of 764 PC patients (Table 1). In 42 (85.7%) of these 49 patients, the lesions were ^{68}Ga-PSMA–avid, whereas in the remaining 7 patients (14.3%), the lesions were detected only on the contemporaneous CT component of the study.

TABLE 1
Summary of Results for 764 Patients

Parameter	No. of patients	Percentage of patients	Follow-up
Suspected second primary malignancy	49	6.4	
PC atypical metastases	8	1.0	
Proven by biopsy			
Lung	2		Lung metastases
Lymph node	2		Atypical nodal metastases
Proven by imaging or clinically			
Lung	2		Lung metastases
Lymph node	2		Nodal metastases
Pathologically proven second primary malignancy	5	0.7	
Thyroid	1		Papillary thyroid carcinoma
Lung	2		1 adenocarcinoma and 1 SCC
Tongue	1		SCC
Lymphoma	1		DLBCL
Proven benign	24	3.1	
Pathologically (thyroid)	1		Hurthle cell adenoma
By endoscopy (larynx)	1		Normal larynx
By imaging or clinically			
Lung	5		3 stable and 2 resolved
Thyroid	4		Stable
Liver	3		2 hemangiomas and 1 resolved
Lymph node	3		Stable
Spleen	2		Stable
Brain	1		Atypical meningioma
Pancreas	1		Stable
Bone	1		Resolved
Soft tissue	1		Stable
Skin	1		Stable
Not yet confirmed	12	1.6	

SCC = squamous cell carcinoma; DLBCL = diffuse large B-cell lymphoma.

In 8 (1.0%) of 764 patients, ^{68}Ga-PSMA–avid lesions were histologically proven to be metastases from PC (Fig. 1) in the lungs (4 cases) and lymph nodes (4 cases). However, in 5 (0.7%) of 764 patients, ^{68}Ga-PSMA–avid lesions were pathologically proven to be synchronous primary malignancies (Figs. 2 and 3). Proven sites were the lungs (2 cases), thyroid (1 case), base of the tongue (1 case), and lymphoma (1 case).

In 22 patients (with lesions in the following locations: 5 lung, 4 thyroid, 3 liver, 3 lymph node, 2 spleen, 1 brain, 1 pancreas, 1 bone, 1 soft tissue, and 1 skin), there was no progression on follow-up imaging (Figs. 4A, 4B, and 4C) or clinical examination, suggesting benign diagnoses. One patient had a normal endoscopic evaluation for a suspected laryngeal lesion, which likely represented physiologic salivary pooling. One thyroid lesion was a biopsy-proven benign hyperplastic nodule (Figs. 4D and 4E). All biopsy-proven cases are shown in Table 2. In 12 (1.6%) of 764 patients, the follow-up record was not yet available or the final diagnosis of the detected lesion had not yet been clarified.

For the 7 patients with ^{68}Ga-PSMA–negative lesions identified on contemporaneous CT, 5 lesions were in the lung and 2 were in the thyroid. PC metastases or additional non-PC malignancies were not confirmed for any of these lesions.

DISCUSSION

PSMA is a transmembrane glycoprotein expressed in normal prostate epithelium but overexpressed in virtually all PCs (*14*). ^{68}Ga-PSMA PET/CT produces images with high tumor-to-background contrast, resulting in high sensitivity and specificity for the detection of PC (*4*). The accuracy of ^{68}Ga-PSMA PET/CT for the detection of PC was recently evaluated in a systematic review and metaanalysis of 16 articles involving studies of 1,309 patients (*15*). As determined by a per-patient analysis, the summary sensitivity and specificity were both 86%.

PSMA is also expressed on the neovasculature of many solid tumors (*16*). Because of the relatively limited clinical experience with

FIGURE 1. Biopsy-confirmed PC. (A and B) Left hilar node (arrows) (SUV$_{max}$, 30). (C and D) Right upper-lobe nodule (arrows) (SUV$_{max}$, 3).


FIGURE 2. Incidental findings on ^{68}Ga-PSMA PET/CT of focal uptake (arrows) (SUV$_{max}$, 5.3) in right oropharynx (A) and ipsilateral mildly enlarged level II lymph nodes (arrows) (SUV$_{max}$, 3.6) (B). Biopsy demonstrated squamous cell carcinoma.

^{68}Ga-PSMA PET/CT, examples of incidental detection of synchronous ^{68}Ga-PSMA–avid malignancies are limited to recent case reports (7–13). In the present study, atypical ^{68}Ga-PSMA–avid lesions were confirmed to be second primary malignancies in only 5 (0.7%) of 764 patients. In our experience, it was more uncommon to encounter ^{68}Ga-PSMA–avid lymph nodes at unexpected locations, either as atypical PC metastases (Fig. 1) or due to additional primary malignancies (Fig. 2). In most cases, the intensity of metabolic activity in nodal or distant metastases parallels that in the primary site of malignancy (17). Therefore, encountering discordant low-grade ^{68}Ga-PSMA activity in multiple enlarged lymph nodes should raise the level of suspicion for a second primary malignancy, such as lymphoma (patient 8 in Table 2). In our experience, a ^{68}Ga-PSMA–avid thyroid lesion could be an exception to the rule for ^{68}Ga-PSMA, in that a benign nodule might present with higher ^{68}Ga-PSMA avidity than the primary PC (Fig. 4; patient 9 in Table 2).

In the present study, lesions atypical for PC metastases (with or without ^{68}Ga-PSMA avidity) were found in 49 (6.4%) of 764 patients. In 8 (1.0%) of 764 patients, atypical ^{68}Ga-PSMA–avid lesions were proven to be metastases from PC. Because of the high sensitivity and specificity of ^{68}Ga-PSMA PET/CT for PC evaluation, differentiation between typical metastases and atypical metastases is evolving as the modality redefines patterns of PC spread. Given the age of patients with PC, encountering lung lesions with or without ^{68}Ga-PSMA avidity is not uncommon, and the degree of uptake may not be reliable for differentiating PC metastases from lung cancer (Fig. 1D vs. Fig. 3). In fact, quantitative analysis of ^{68}Ga-PSMA PET/CT results does not reliably discriminate between pulmonary metastases and primary lung cancer in PC patients (9). Therefore, isolated atypical ^{68}Ga-PSMA–avid lung lesions may need pathologic confirmation. Also, non–^{68}Ga-PSMA–avid lung lesions may need further CT surveillance, ^{18}F-FDG PET/CT, or biopsy.

In 24 (3.1%) of 764 patients, atypical lesions (with or without ^{68}Ga-PSMA avidity) had a benign etiology, as determined by additional follow-up imaging or investigations. To confirm benign causes, stability over time should be confirmed. Also, in the absence of nodal disease, an isolated ^{68}Ga-PSMA–avid lesion at an atypical location is unlikely to be a PC-related distant metastasis. For example, liver metastases from PC are typically multiple, so an isolated ^{68}Ga-PSMA–avid liver lesion as the only metastatic site is less likely. In such cases, multiphase CT or MRI should be performed for further characterization (Fig. 4).

Correct and careful interpretation of the CT scan as part of a ^{68}Ga-PSMA PET/CT examination is of special importance, not only for differentiating physiologic uptake in ganglia or ureters

FIGURE 3. Maximum-intensity projection (A) and fused axial PET/CT and CT (B) showing focal uptake (arrows) (SUV$_{max}$, 7) in small right hilar mass on background of more intense uptake in several pelvic nodes (SUV$_{max}$, 79). Biopsy demonstrated lung adenocarcinoma.

FIGURE 4. Maximum-intensity projection (A), PET/CT (B), and delayed contrast MRI (C) showing small liver lesion (arrow) (SUV_{max}, 15), with no abnormality seen on low-dose CT. MRI demonstrated arterial-phase enhancement matching blood pool, consistent with hemangioma. Maximum-intensity projection (D) and fused axial PET/CT and CT (E) showing 40-mm thyroid nodule (arrow) (SUV_{max}, 6.3). Ultrasound demonstrated predominantly solid, mainly hyperechoic lesion with low-echo rim and increased vascularity. Biopsy demonstrated benign hyperplastic nodule (Bethesda category 2).

from that in lymph nodes but also for the detection of non–[68]Ga-PSMA–avid lesions. Seven (14.3%) of 49 patients with lesions atypical for PC metastases had non–[68]Ga-PSMA–avid lesions detected only on the CT component of the PET/CT examination (5 lung and 2 thyroid). However, none of these was a second primary malignancy or metastasis from PC, suggesting that indeterminate CT findings are frequently benign. Because intravenous contrast material was not routinely used for the contemporaneous CT for all patients, non–[68]Ga-PSMA–avid but morphologically suggestive lesions could have been underestimated in our analysis.

The present study was limited by retrospective analysis. The reporting styles of readers vary, and our results might not be generalizable to other centers. We aimed to

TABLE 2
Pathology-Proven Cases

Patient no.	Age (y)	Presence in prostate, nodal metastases, or distant metastases	^{68}Ga-PSMA SUV_{max}	Size of metastasis (cm)	Location of suspected lesion	Size of suspected lesion (cm)	^{68}Ga-PSMA SUV_{max}	Biopsy result
1	77	Prostate-negative			Lung	0.9 × 1.1	1.6	Lung metastases (PC)
		Right external iliac LN	3.7	1.3 × 1.4				
2	69	Prostate-negative			Right upper lung	1 × 1.2	3.4	Lung metastases (PC)
		Node-negative			Right lower lung	1.7 × 2.0	2.3	
3	75	Prostate-negative			Hilar LN	1.3 × 1.5	30.3	Nodal metastases (PC)
		Right external iliac LN	53.4	0.7 × 1.2				
		Left external iliac LN	40.4	1.1 × 1.6				
4	59	Prostate-negative			Thyroid nodule	0.7	1.9	Papillary thyroid carcinoma
		Left external iliac LN	12.2	1.0 × 3.4				
		Bone metastases	29.2					
5	67	Prostate	14.4	4.5 × 3.7	Lung	1.8 × 1.6	3.7	Lung adenocarcinoma
		Node-negative						
6	69	Prostate-negative			Lung	1.6 × 2.4	7	Lung adenocarcinoma
		Right external iliac LN	23	0.6 × 0.9				
		Left external iliac LN	79	2.8 × 2.1				
7	55	Prostate-negative			Right cervical LN	2.0 × 2.4	3.6	Tongue base SCC
					Tongue base		5.3	
8	78	Prostate	26.1	2.3 × 1.4	Left paraaortic LN	1.7 × 1.7	2.6	Lymphoma (DLBCL)
9	70	Prostate-negative			Right thyroid nodule	3.0 × 3.2	6.3	Benign hyperplastic nodule
		Left pelvic LN	3.6	0.6 × 1.0				
		Osseous metastases	20.6					

LN = lymph node; SCC = squamous cell carcinoma; DLBCL = diffuse large B-cell lymphoma.

report with high specificity, acknowledging the consequent trade-off in sensitivity, to minimize the likelihood of adverse patient outcomes from false-positive results (*17*). In addition, the advanced stage of PC patients undergoing ^{68}Ga-PSMA PET/CT, coupled with the relatively short follow-up period and high percentage of cases from remote facilities, led to a relatively high number of patients without a follow-up record or a final diagnosis for the detected lesion.

CONCLUSION

Synchronous ^{68}Ga-PSMA–avid malignancies were rare (0.7%) in PC patients with atypical lesions, which were more commonly unusual PC metastases (1.0%) or benign (3.1%). These findings support the high specificity of ^{68}Ga-PSMA PET/CT for PC, with further investigations for atypical ^{68}Ga-PSMA–avid lesions or CT findings being required in a minority of cases.

DISCLOSURE

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin.* 2016;66:7–30.
2. Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic efficacy of gallium-PSMA positron emission tomography compared to conventional imaging in lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. *J Urol.* 2016;195:1436–1443.
3. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid ^{68}Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. *J Nucl Med.* 2015;56:668–674.
4. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the ^{68}Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. *Eur J Nucl Med Mol Imaging.* 2015;42:197–209.
5. Kanthan GL, Drummond J, Schembri GP, et al. Follicular thyroid adenoma showing avid uptake on ^{68}Ga PSMA-HBED-CC PET/CT. *Clin Nucl Med.* 2016;41:331–332.
6. Krohn T, Verburg FA, Pufe T, et al. [^{68}Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical. practice. *Eur J Nucl Med Mol Imaging.* 2015;42:210–214.
7. Schwenck J, Tabatabai G, Skardelly M, et al. In vivo visualization of prostate specific membrane antigen in glioblastoma. *Eur J Nucl Med Mol Imaging.* 2015;42:170–171.
8. Rowe SP, Groin MA, Hammers HJ, et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ^{18}F-DCFPyL PET/CT. *Ann Nucl Med.* 2015;29:877–882.
9. Pyka T, Weirich G, Einspieler I, et al. ^{68}Ga-PSMA-HBED-CC PET for differential diagnosis of suggestive lung lesions in patients with prostate cancer. *J Nucl Med.* 2016;57:367–371.
10. Verburg FA, Krohn T, Heinzel A, Mottaghy FM, Behrendt FF. First evidence of PSMA expression in differentiated thyroid cancer using [^{68}Ga]PSMA-HBED-CC PET/CT. *Eur J Nucl Med Mol Imaging.* 2015;42:1622–1623.
11. Sathekge M, Modiselle M, Vorster M, et al. ^{68}Ga-PSMA imaging of metastatic breast cancer. *Eur J Nucl Med Mol Imaging.* 2015;42:1482–1483.
12. Huang YT, Fong W, Thomas P. Rectal carcinoma on ^{68}Ga-PSMA PET/CT. *Clin Nucl Med.* 2016;41:e167–e168.
13. Sasikumar A, Joy A, Nanabala R, et al. ^{68}Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma. *Eur J Nucl Med Mol Imaging.* 2016;43:795–796.
14. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. *J Cell Biochem.* 2004;91:528–539.
15. Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive ^{68}Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. *Eur Urol.* 2016;70:926–937.
16. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. *Clin Cancer Res.* 1999;5:2674–2681.
17. Hofman MS, Hicks RJ. How we read oncologic FDG PET/CT. *Cancer Imaging.* 2016;16:35–49.